Theradiag

Theradiag EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Theradiag (ALTER.PA) as of Oct 29, 2026 is -366,000.00 EUR. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -283,300.00 EUR — a change of 29.19% (lower).

EBITDA

-366,000.00EUR

YoY

29.19%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Theradiag is 2022 -366,000.00 EUR. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Theradiag was 2021 -283,300.00 EUR. It decreases by 29.19% lower compared to the previous year.

The Theradiag EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2015
-2.78 M EUR
Jan 1, 2016
-1.49 M EUR
Jan 1, 2017
-1.79 M EUR
Jan 1, 2018
-140,700.00 EUR
Jan 1, 2019
-76,600.00 EUR
Jan 1, 2020
-51,100.00 EUR
Jan 1, 2021
-283,300.00 EUR
Jan 1, 2022
-366,000.00 EUR
The Theradiag EBITDA history
YEAREBITDAYoY
-366,000.00EUR+29.19%
-283,300.00EUR+454.40%
-51,100.00EUR-33.29%
-76,600.00EUR-45.56%
-140,700.00EUR-92.12%
-1.79 MEUR+19.71%
-1.49 MEUR-46.41%
-2.78 MEUR+2.91%
-2.70 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Theradiag Stock analysis

What does Theradiag do? Theradiag SA is a French company specialized in the development, production, and marketing of diagnostics for personalized medicine. The company was founded in 1986 and is headquartered in Marne-la-Vallée, France. It is listed on the stock exchange and belongs to the Euronext Growth market segment. Theradiag offers diagnostics for autoimmune, infectious, cancer, and inflammatory diseases. Its business model involves developing innovative diagnostics and selling them to clinical laboratories and hospitals. The company has a network of distributors to sell its products globally. Its offerings include diagnostics for autoimmune diseases, infections, cancer, and inflammation, as well as personalized medicine. The company invests in research and development to improve patients' health and well-being. Theradiag is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Theradiag stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Theradiag is -366,000.00 EUR in 2022.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Theradiag changed from -283,300.00 EUR to -366,000.00 EUR, representing a 29.19% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Theradiag since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Theradiag historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Theradiag

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Theradiag